Online inquiry

IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2251MR)

This product GTTS-WQ2251MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Lama glama
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2251MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1470MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ14294MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ6217MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ11845MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ10957MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ14779MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ2709MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ11463MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW